Medical Research,Tokushima University, Nakashowa 1-61,Tokushima 7700943, Japan; Shikoku Island Division, Integrative Medicine Japan (IMJ),Tokushima University, Nakashowa 1-61,Tokushima 7700943, JapanJapan
Also available as PDF (figures and tables appear in the PDF).
Recently, elder patients tend to have neuropathic pain such as lower back and joints pain, stiff shoulders, besides diabetic neuropathy. Typical peripheral neuropathic pain includes diabetic peripheral neuropathic pain (DPNP), postherpetic neuralgia (PHN) and chronic pain due to herniated disc. Three analgesic agents are described. Pregabalin (Lyrica®) has been prevalent worldwide. However, it has been provided for several diseases for off-label administration, which has been one of the clinical problems.Mirogabalin (Tarlige®) has revealed efficacy for DPNP in a dose-dependent manner. Duloxetine hydrochloride (Cymbalta ®) has efficacy for pain and also depression as serotonin and noradrenaline reuptake inhibitor (SNRI).
Keywords: Neuropathic pain; Pregabalin; Mirogabalin; Duloxetine hydrochloride; Diabetic peripheral neuropathic pain (DPNP); Neuropathic pain; Pregabalin; Mirogabalin; Duloxetine hydrochloride
Recently, elder patients tend to have neuropathic pain such as lower back and joints pain, stiff shoulders, besides diabetic neuropathy. Typical peripheral neuropathic pain includes diabetic peripheral neuropathic pain (DPNP), postherpetic neuralgia ® (PHN) and chronic pain due to herniated disc. Three analgesic agents are described. Pregabalin (Lyrica®) has been prevalent worldwide. However, it has been provided for several diseases for off-label administration, which has been one of the clinical ® problems.Mirogabalin (Tarlige®) has revealed efficacy for DPNP in a dose-dependent manner. Duloxetine hydrochloride (Cym- ® balta®) has efficacy for pain and also depression as serotonin and noradrenaline reuptake inhibitor (SNRI). Keywords Neuropathic pain; Pregabalin; Mirogabalin; Duloxetine hydrochloride; Diabetic peripheral neuropathic pain (DPNP). Abbreviations DPNP: Diabetic peripheral neuropathic pain; PHN: Postherpetic neuralgia; CRPS: Complex regional pain syndrome; FDA: Food and Drug Administration.
n primary care medicine, the number of elderly outpatients has is some difference in the perception between patients and medical increased in recent years. Regarding common health problems, professionals.2 I general medicine region includes non-communicable diseases (NCD) such as diabetes mellitus, and orthopedic region includes The progress situation of numbness and pain has been 1 3 low back pain, knee joint pain and shoulder stiffness.1 Statistic sur- important.3 For example, low back pain is classified into three vey of lifestyle revealed the health and medical complaints of peo- types due to persisting period, which are acute less than 4-weeks, ple. They include several popular symptoms in order as follows: subacute for 4-weeks to 3-months, and chronic for more than man showed lower back pain, stiff shoulders, joints pain and wom- 3-months. As described above, detail medical interviews, diagnosis 1 and treatment would be crucial for patients with diabetic neuropa- an showed stiff shoulder, lower back pain, joints pain, respectively. thy, orthopedic neuropathy and other impaired states. Patients often complain of numbness. This includes sev- Recently, comprehensive medical term “neuropathic eral situations as follows: i) tingling abnormal sensations that are 2,3 pain” has been widely prevalent. It is also used in the documents close to pain, ii) the sensation of the skin is dull, and iii) the move- in U.S. Food and Drug Administration (FDA), such as manage- ment of extremities are stiff and rigid. Thus, various conditions are ment of neuropathic pain associated with diabetic peripheral neu- observed for the combination of numbness and neuralgia. There ropathy and spinal cord injury.
cc Copyright 2020 by Bando H. This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited. Neuropathic pain has a variety of causes, including trau- This medicine Mirogabalin has been known and used ® matic, infectious, nutritional metabolism, toxic, neoplastic and widely as Tarlige® (DS-5565). This name is from the combination compression/strangulation.3 They are also classified according to of targeting and ligand. As a matter of fact, a high prevalence of whether the affected nerves are central (brain or spinal cord) or painful DPN has been observed with about one-third of diabetic peripheral (terminals such as limbs). The typical examples of pe- patients.12 According to the study of maximum observed effect ripheral neuropathic pain would be shown as follows: i) diabetic (Emax) for Pregabalin and Mirogabalin, therapeutic doses of the peripheral neuropathic pain (DPNP), ii) postherpetic neuralgia latter showed limited evidence of abuse potential.13 (PHN), iii) chronic pain due to herniated disc.
The third is duloxetine hydrochloride (D01179) (Cymbal- ® 14 In the category of neuropathic pain, there are rare but ta®).14 As a standard treatment for administration of the analgesics, important diseases. One is allodynia, where pain is caused by a the recommended agents for neuropathic pain have been Pregaba- stimulus that does not usually elicit pain. The other is complex lin (evidence level 1A), duloxetine hydrochloride (Cymbalta) (1A), regional pain syndrome (CRPS), also known as reflex sympathetic and Amitriptyline Hydrochloride (Tryptanol) (1B).15 Duloxetine dystrophy (RSD).4 CRPS is characterized by continuing regional is categorized as serotonin and noradrenaline reuptake inhibitor pain that seems disproportionate in time, degree or region. Regard- (SNRI), that is effective for depressive state. It has been widely ing the analgesics for reducing pain, three kinds of medicine would used for diabetic neuropathy.16 be described in this article.
The indication includes diabetic neuropathy, fibromyal- ® 15 The first medicine is Pregabalin (trade name: Lyrica®) gia, chronic low back pain, osteoarthritis and others.15 In contrast, (D02716). The indication has been neuropathic pain whose effects its contraindications include severe liver and kidney impairment, were demonstrated in fibromyalgia, postherpetic neuralgia, and hypersensitivity, glaucoma, and so on.17 As for the method of pain after spinal cord injury. However, in daily medical practice, intaking medicine, Pregabalin and Mirogabalin are administered it has been often used for low back pain, sciatica and joint pain.5 twice a day, while duloxetine is administered once a day. Therefore, From 58 available literatures, clinical abuse potential of pregabalin compliance and adherence seem to be better in duloxetine. was suggested and prescribers had to pay attention to this situation 5 Pregabalin has been very common medicine in terms especially for patients with abuse of some medicine. of drug sales. In Japan, pregabalin is the number one sales agent Patients having pain deserve attention, empathy, time and among all medical agents sold in Japan. Behind this situation, how- understanding.6 Some patients may receive efficacy from trial of ever, there have been many off-label administrations that deviate gabapentin or pregabalin for off-label indications. However, pre- from conventional rules. Consequently, drug abuse has been con- scribers do not have to think that these medicines show effect for tinued for diseases with indeterminate efficacy.
pain of most pain syndromes.6 The comparative study for groups 7 Furthermore, cost-effectiveness analyses (CEAs) would of gabapentin (n=362) and pregabalin (n=362) was conducted. As a result, clinicians providing these medicines for pain should be important in this region. There have been several CEAs for neu- recognize the limited evidence and explain the patients uncertain ropathic pain, in which heterogeneous factors are present such as 7 methodology, design, treatments and perspectives for influencing benefits for off-label administration.
cost-effectiveness of health condition and pain relief.18 For initial There have been increasing of intentional gabapentin treatment for DPNP, National Institute for Health and Care Ex- misuse.8 In order to determine the pharmacovigilance abuse sig- cellence (NICE) shows the recommendation of amitriptyline, du- nals for gabapentin, FDA adverse events reports from 2005 to loxetine, pregabalin or gabapentin.19 However, there was not clear 20,21 2015 (6 million) were investigated with gabapentin reports (0.1 consensus concerning the treatments for neuropathic pain. In million). Compared to duloxetine, gabapentin had significantly the light of CEAs for DPNP, clinically beneficial and tolerated greater odds of a co-report for an abuse-related and abuse-specific treatment choice has been studied by optimal pathway for treat- adverse event (AS-AE).8 ing neuropathic paiN in diabetes mellitus (OPTION-DM) study.22 Recent CEAs include systematic reviews focusing on strength and The second is Mirogabalin. This is also ligand for the limitation of data and modeling practices.
α2δ subunit of voltage-gated calcium channels as Pregabalin.9 It has been developed to reduce several pains associated with DPN In summary, current topics concerning neuropathic pain (diabetic peripheral neuropathy) and postherpetic neuralgia.9 Re- and its related medical agents were described in this article. Among garding the adequate therapy of Mirogabalin, various doses of them, proper diagnosis and treatment of medical agents would 5, 10, 15, 20, 30 mg/day was provided for patients with DPNP.10 be necessary. This comment will be hopefully useful for adequate Treatment effect least squares (LS), adverse events (AEs) and other therapy in the medical practice.
biomarkers were studied. As a result, doses of 15, 20, 30 mg/day had statistically significant reductions in average daily pain score ETHICAL CONSIDERATIONS (ADPS) and Mirogabalin may become a promising new option for As regard to this report, author has established an ethical commit- DPNP. Mirogabalin revealed efficacy for DPNP in a dose-depen- tee in the Integrative Medicine Japan, Shikoku island division. It dent manner. Mirogabalin given 30 mg/day showed statistically included the director, vice-director, expert in the pharmacology, significant reduced pain in Asian patients. All doses of Mirogabalin nursing and legal specialties. We have discussed and made confir- tested were well tolerated.
mation that current report was valid and agreed with all members 10. VinikA, Rosenstock J, Sharma U, Feins K, Hsu C, Merante without any problems.
D. Efficacy and safety of mirogabalin (DS-5565) for the treat- ment of diabetic peripheral neuropathic pain: A randomized, FUNDING double-blind, placebo- and active comparator–controlled, adap- tive proof-of-concept phase 2 study. Diabetes Care. 2014; 37(12): The author does not have any funding concerning this report. 3253-3261. doi: 10.2337/dc14-1044 CONFLICT OF INTEREST 11. Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Miro- gabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase 3 study The authors declare that they have no conflicts of interest. in Asian patients. Journal of Diabetes Investigation. 2019; 10(5): doi: 10.1111/jdi.13013